
1. j natl cancer inst. 2010 mar 3;102(5):358-9; author reply 359-60.

response: re: cost-effectiveness analysis human papillomavirus vaccination 
the netherlands.

rozenbaum mh, boersma c.

comment on
    j natl cancer inst. 2009 aug 5;101(15):1083-92.

doi: 10.1093/jnci/djp519 
pmid: 20229619  [indexed medline]

